Cantor Fitzgerald reaffirmed their buy rating on shares of Spark Therapeutics, Inc. (NASDAQ:ONCE) in a report issued on Friday. Cantor Fitzgerald also issued estimates for Spark Therapeutics’ FY2017 earnings at ($7.27) EPS and FY2018 earnings at ($5.54) EPS.

Other research analysts have also recently issued research reports about the company. Jefferies Group LLC reissued a buy rating and issued a $95.00 price objective (up previously from $85.00) on shares of Spark Therapeutics in a research report on Thursday, August 3rd. Evercore ISI began coverage on Spark Therapeutics in a research report on Wednesday, August 16th. They issued an in-line rating and a $83.00 price objective on the stock. Zacks Investment Research raised Spark Therapeutics from a strong sell rating to a hold rating in a research report on Wednesday, July 19th. Chardan Capital reissued a neutral rating on shares of Spark Therapeutics in a research report on Monday, July 24th. Finally, BidaskClub raised Spark Therapeutics from a sell rating to a hold rating in a research report on Thursday, June 22nd. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and thirteen have assigned a buy rating to the company. The stock has an average rating of Buy and an average target price of $82.32.

Shares of Spark Therapeutics (ONCE) opened at 81.51 on Friday. The company’s 50 day moving average is $71.59 and its 200 day moving average is $61.05. The firm’s market capitalization is $2.55 billion. Spark Therapeutics has a 12-month low of $35.07 and a 12-month high of $83.19.

Spark Therapeutics (NASDAQ:ONCE) last posted its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($1.89) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.75) by $0.14. Spark Therapeutics had a negative return on equity of 59.74% and a negative net margin of 962.72%. The business had revenue of $1.48 million during the quarter, compared to analysts’ expectations of $1.33 million. During the same period in the prior year, the firm posted ($1.04) EPS. The firm’s revenue for the quarter was up 14.7% on a year-over-year basis. On average, analysts forecast that Spark Therapeutics will post ($7.75) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Spark Therapeutics, Inc. (ONCE) Given “Buy” Rating at Cantor Fitzgerald” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another website, it was illegally stolen and reposted in violation of US & international copyright & trademark laws. The correct version of this piece can be read at https://www.thecerbatgem.com/2017/08/29/spark-therapeutics-inc-once-given-buy-rating-at-cantor-fitzgerald.html.

In other news, General Counsel Barge Joseph La sold 5,000 shares of the company’s stock in a transaction on Wednesday, June 7th. The stock was sold at an average price of $55.00, for a total transaction of $275,000.00. Following the transaction, the general counsel now owns 9,567 shares of the company’s stock, valued at approximately $526,185. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Jeffrey D. Marrazzo sold 21,350 shares of the company’s stock in a transaction on Wednesday, August 23rd. The shares were sold at an average price of $80.01, for a total value of $1,708,213.50. Following the transaction, the chief executive officer now directly owns 251,350 shares in the company, valued at approximately $20,110,513.50. The disclosure for this sale can be found here. Insiders have sold a total of 360,660 shares of company stock worth $25,495,351 in the last ninety days. Insiders own 7.30% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Teachers Advisors LLC boosted its position in shares of Spark Therapeutics by 16.8% in the fourth quarter. Teachers Advisors LLC now owns 33,884 shares of the biotechnology company’s stock worth $1,691,000 after buying an additional 4,875 shares in the last quarter. Nationwide Fund Advisors raised its stake in Spark Therapeutics by 2.5% in the first quarter. Nationwide Fund Advisors now owns 17,298 shares of the biotechnology company’s stock worth $923,000 after buying an additional 414 shares during the last quarter. Wells Fargo & Company MN raised its stake in Spark Therapeutics by 131.8% in the first quarter. Wells Fargo & Company MN now owns 522,894 shares of the biotechnology company’s stock worth $27,891,000 after buying an additional 297,277 shares during the last quarter. Tocqueville Asset Management L.P. raised its stake in Spark Therapeutics by 10.1% in the first quarter. Tocqueville Asset Management L.P. now owns 59,850 shares of the biotechnology company’s stock worth $3,192,000 after buying an additional 5,500 shares during the last quarter. Finally, American Century Companies Inc. raised its stake in Spark Therapeutics by 0.7% in the first quarter. American Century Companies Inc. now owns 488,519 shares of the biotechnology company’s stock worth $26,058,000 after buying an additional 3,445 shares during the last quarter. 91.01% of the stock is currently owned by hedge funds and other institutional investors.

Spark Therapeutics Company Profile

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Analyst Recommendations for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Stock Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related stocks with our FREE daily email newsletter.